Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Net Cash Flow (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Net Cash Flow for 4 consecutive years, with -$2.5 million as the latest value for Q4 2024.

  • Quarterly Net Cash Flow rose 23.87% to -$2.5 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$13.9 million through Dec 2024, up 15.29% year-over-year, with the annual reading at $48.3 million for FY2025, 613.71% up from the prior year.
  • Net Cash Flow hit -$2.5 million in Q4 2024 for Pasithea Therapeutics, up from -$3.1 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $32.4 million in Q4 2021 to a low of -$7.0 million in Q3 2023.
  • Historically, Net Cash Flow has averaged $508473.9 across 4 years, with a median of -$3.1 million in 2023.
  • Biggest five-year swings in Net Cash Flow: crashed 360.45% in 2022 and later soared 55.72% in 2024.
  • Year by year, Net Cash Flow stood at $32.4 million in 2021, then plummeted by 117.06% to -$5.5 million in 2022, then skyrocketed by 41.39% to -$3.2 million in 2023, then grew by 23.87% to -$2.5 million in 2024.
  • Business Quant data shows Net Cash Flow for KTTA at -$2.5 million in Q4 2024, -$3.1 million in Q3 2024, and -$4.0 million in Q2 2024.